The FDA announced their emergency authorization for the use of InspectIR COVID-19 Breathalyzer for use.
The product is approximately the size of a carry-on suitcase and can be used in doctor’s offices, hospitals, and mobile testing sites and test results will be provided in less than three minutes. The purpose of the test is to detect chemical compounds that are interconnected with the coronavirus.
The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor’s offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage.
Recent data revealed that the InspectIR was able to accurately identify over 91% of positive results of covid samples and nearly 100 % after 2,409 people participated in a study with or without symptoms of the virus.